The DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index.
Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases
Open accessAbstract
IDH1 and IDH2 mutations occur frequently in gliomas and acute myeloid leukemia, leading to simultaneous loss and gain of activities in the production of α-ketoglutarate (α-KG) and 2-hydroxyglutarate (2-HG), respectively. Here we demonstrate that 2-HG is a competitive inhibitor of multiple α-KG-dependent dioxygenases, including histone demethylases and the TET family of 5-methlycytosine (5mC) hydroxylases. 2-HG occupies the same space as α-KG does in the active site of histone demethylases. Ectopic expression of tumor-derived IDH1 and IDH2 mutants inhibits histone demethylation and 5mC hydroxylation. In glioma, IDH1 mutations are associated with increased histone methylation and decreased 5-hydroxylmethylcytosine (5hmC). Hence, tumor-derived IDH1 and IDH2 mutations reduce α-KG and accumulate an α-KG antagonist, 2-HG, leading to genome-wide histone and DNA methylation alterations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, it is plausible that increased levels of 2-HG may enable a switch to an entirely HIF-independent mechanism.”
From HIF-1-Independent Mechanisms Regulating Metabolic Adaptation in Hypoxic Cancer Cells (2021) · cites this paper as [152]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Mutant IDH protein produces a novel onco-metabolite, 2-hydroxyglutarate (2-HG), that interferes with iron-dependent hydroxylases, including the TET family of 5′-methylcytosine hydroxylases3–7.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [5]
The cited source says what the claim attributes to it.
In the citing paper
“Mutant IDH protein produces a novel onco-metabolite, 2-hydroxyglutarate (2-HG), that interferes with iron-dependent hydroxylases, including the TET family of 5′-methylcytosine hydroxylases3–7.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [5]
In the citing paper
“The observation that IDH1 and IDH2 mutations can partially phenocopy the loss of TET function may explain the mutual exclusivity of these mutations in cancer 95,97 .”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [97]
In the citing paper
“Mutant IDH protein is a competitive inhibitor of hydroxylases, including the TET family of 5mC hydroxylases120–122.”
From Transcription factors as readers and effectors of DNA methylation (2016) · cites this paper as [122]
In the citing paper
“These observations support a model in which PU.1 guides TET2 to a specific subset of genomic regions to facilitate the oxidation of 5mC to 5hmC, a reaction that is inhibited by 2-hydroxyglutarate47 and enhanced by vitamin C13 (Figure 5d).”
From Vitamin C-induced epigenomic remodelling in IDH1 mutant acute myeloid leukaemia (2018) · cites this paper as [47]
In the citing paper
“In the cancer setting, 2-HG has been shown to influence a number of biological processes, including cell differentiation, DNA methylation, and histone methylation (79–82), leading to its classification as an oncometabolite.”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [81]
In the citing paper
“For example, 2-HG acts as a competitive inhibitor of α-KG, and its production by mutant IDH1 consumes α-KG (81, 99), leading to reduced TET2 and JmjC activity in tumor cells (79, 80).”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [81]
In the citing paper
“Furthermore, TH17 cell differentiation could be initiated by exogenous addition of D-2-HG to naïve CD4+ T cells or by genetic silencing of TET1 and TET2, established targets of 2-HG143-145.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [145]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1
Tahiliani, M., Koh, K. P., Shen, Y., Pastor, W. A., Bandukwala, H., Brudno, Y., Agarwal, S., Iyer, L. M., Liu, D. R., Aravind, L., et al. (2009) · Science · doi:10.1126/science.1170116 · Cited by 5,836
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735 · cited 2×
“HIF-1a is a transcription factor whose function is linked to metabolism, angiogenesis and tumorigenesis, and whose protein level is downregulated under normoxic conditions by PHD-mediated hydroxylation and subsequent hydroxylation-targeted ubiquitination (Bruick and McKnight, 2001; Epstein et al., 2001; Ivan et al., 2…”
Self-citationEndostatin: an endogenous inhibitor of angiogenesis and tumor growth
O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Epstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333
Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766
Flagged first, then by citations
1 of the 55 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Han, 2007, Structural basis for histone demethylation by JHDM1, Frontier Science, 1, 52
Cited by
Sorted by citations
Items 301–400 of 1,006
Leu, S., von Felten, S., Frank, S., Vassella, E., Vajtai, I., Taylor, E., Schulz, M., Hütter, G., Hench, J., Schucht, P., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/nos317 · Cited by 191
Metabolic rewiring in the promotion of cancer metastasis: mechanisms and therapeutic implications
Wei, Q., Qian, Y., Yu, J. Q., & Wong, C. C. (2020) · Oncogene · doi:10.1038/s41388-020-01432-7 · Cited by 193
Janke, R., Dodson, A. E., & Rine, J. (2015) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-100814-125544 · Cited by 199
Whole-Exome Sequencing Identifies MDH2 as a New Familial Paraganglioma Gene
Cascón, A., Comino‐Méndez, I., Currás-Freixes, M., de Cubas, A. A., Contreras, L., Richter, S., Peitzsch, M., Mančíková, V., Inglada‐Pérez, L., Pérez‐Barrios, A., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv053 · Cited by 204
The emerging role of fumarate as an oncometabolite
Yang, M., Soga, T., Pollard, P. J., & Adam, J. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00085 · Cited by 189
Driver mutations of cancer epigenomes
Roy, D. M., Walsh, L. A., & Chan, T. A.-T. (2014) · Protein & Cell · doi:10.1007/s13238-014-0031-6 · Cited by 188
Proto-Oncogenic Role of Mutant IDH2 in Leukemia Initiation and Maintenance
Kats, L. M., Reschke, M., Taulli, R., Pozdnyakova, O., Burgess, K., Bhargava, P., Straley, K. S., Karnik, R., Meissner, A., Small, D., et al. (2014) · Cell stem cell · doi:10.1016/j.stem.2013.12.016 · Cited by 200
Self-citationThe CpG Island Methylator Phenotype: What's in a Name?
Hughes, L., Melotte, V., Schrijver, J. M. D., de Maat, M., Smit, V. T. H. B. M., Bovée, J. V. M. G., French, P. J., van den Brandt, P. A., Schouten, L. J., Meyer, T. D., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4306 · Cited by 182
Long-Term Survival in Primary Glioblastoma With Versus Without Isocitrate Dehydrogenase Mutations
Hartmann, C. J., Hentschel, B., Simon, M., Westphal, M., Schackert, G., Tonn, J. C., Loeffler, M., Reifenberger, G., Pietsch, T., von Deimling, A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0017 · Cited by 186
Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes
Matre, P., Velez, J., Jacamo, R., Qi, Y., Su, X., Cai, T., Chan, S. M., Lodi, A., Sweeney, S. R., Ma, H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12944 · Cited by 185
Moreno‐Sánchez, R., Marín‐Hernández, Á., Saavedra, E., Pardo, J. P., Ralph, S. J., & Rodríguez‐Enríquez, S. (2014) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2014.01.025 · Cited by 189
Glioma Biology and Molecular Markers
Cohen, A. L., & Colman, H. (2014) · Cancer treatment and research · doi:10.1007/978-3-319-12048-5_2 · Cited by 184
Metabolic Plasticity in Chemotherapy Resistance
Desbats, M. A., Giacomini, I., Prayer‐Galetti, T., & Montopoli, M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00281 · Cited by 190
Chen, C., Liu, Y., Lü, C., Cross, J. R., Morris, J. P., Shroff, A., Ward, P. S., Bradner, J. E., Thompson, C. B., & Lowe, S. W. (2013) · Genes & Development · doi:10.1101/gad.226613.113 · Cited by 186
Self-citationMolenaar, R. J., Radivoyevitch, T., Maciejewski, J. P., Noorden, C. J. F. V., & Bleeker, F. E. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.05.004 · Cited by 186
Ward, P. S., Lü, C., Cross, J. R., Abdel-Wahab, O. I., Levine, R. L., Schwartz, G. K., & Thompson, C. B. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.435495 · Cited by 188
Psat1-Dependent Fluctuations in α-Ketoglutarate Affect the Timing of ESC Differentiation
Hwang, I.-Y., Kwak, S., Lee, S., Kim, H., Lee, S. E., Kim, J.-H., Kim, Y. A., Jeon, Y. K., Chung, D. H., Jin, X., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.014 · Cited by 180
The oncometabolite 2-hydroxyglutarate activates the mTOR signalling pathway
Carbonneau, M., M. Gagné, L., Lalonde, M.-E., Germain, M.-A., Motorina, A., Guiot, M.-C., Secco, B., Vincent, E. E., Tumber, A., Hulea, L., et al. (2016) · Nature Communications · doi:10.1038/ncomms12700 · Cited by 180
Metabolic Heterogeneity of Cancer Cells: An Interplay between HIF-1, GLUTs, and AMPK
Moldogazieva, N. T., Mokhosoev, I. M., & Terentiev, A. A. (2020) · Cancers · doi:10.3390/cancers12040862 · Cited by 181
Redox Potential of Antioxidants in Cancer Progression and Prevention
George, S., & Abrahamse, H. (2020) · Antioxidants · doi:10.3390/antiox9111156 · Cited by 187
Applications of metabolomics to study cancer metabolism
Kaushik, A. K., & DeBerardinis, R. J. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.04.009 · Cited by 179
Oncometabolites: Unconventional triggers of oncogenic signalling cascades
Sciacovelli, M., & Frezza, C. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.04.025 · Cited by 184
Seim, G. L., Britt, E. C., John, S. V., Yeo, F. J., Johnson, A. R., Eisenstein, R. S., Pagliarini, D. J., & Fan, J. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0083-2 · Cited by 179
Metabolic reprogramming in cholangiocarcinoma
Raggi, C., Taddei, M. L., Rae, C. J., Braconi, C., & Marra, F. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.04.038 · Cited by 179
Orr, B. A., Haffner, M. C., Nelson, W. G., Yegnasubramanian, S., & Eberhart, C. G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041036 · Cited by 180
Cassim, S., Vučetić, M., Ždralević, M., & Pouysségur, J. (2020) · Cancers · doi:10.3390/cancers12051119 · Cited by 183
Dinardo, C. D., Stein, A. S., Stein, E. M., Fathi, A. T., Frankfurt, O., Schuh, A. C., Döhner, H., Martinelli, G., Patel, P. A., Raffoux, E., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01632 · Cited by 180
A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylationPreprint
Duncan, C. G., Barwick, B. G., Jin, G., Rago, C., Kapoor-Vazirani, P., Powell, D. R., Chi, J., Bigner, D. D., Vertino, P. M., & Yan, H. (2012) · Genome Research · doi:10.1101/gr.132738.111 · Cited by 183
Acute myeloid leukemia—Major progress over four decades and glimpses into the future
Kantarjian, H. M. (2015) · American Journal of Hematology · doi:10.1002/ajh.24246 · Cited by 174
Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate
Andronesi, O. C., Rapalino, O., Gerstner, E. R., Chi, A. S., Batchelor, T. T., Cahill, D. P., Sorensen, A. G., & Rosen, B. R. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67229 · Cited by 178
Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma
Boerner, T., Drill, E. N., Pak, L. M., Nguyen, B., Sigel, C., Doussot, A., Shin, P. J., Goldman, D. A., Gönen, M., Allen, P. J., et al. (2021) · Hepatology · doi:10.1002/hep.31829 · Cited by 170
Metabolic changes in cancer: beyond the Warburg effect
Wu, W., & Zhao, S. (2013) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gms104 · Cited by 173
Self-citationKernytsky, A. M., Wang, F., Hansen, E., Schalm, S. S., Straley, K. S., Gliser, C., Yang, H. Q., Travins, J. M., Murray, S., Dorsch, M., et al. (2014) · Blood · doi:10.1182/blood-2013-10-533604 · Cited by 181
Self-citationPrecision medicine: Concept and tools
Naithani, N., Sinha, S., Misra, P., Vasudevan, B., & Sahu, R. (2021) · Medical Journal Armed Forces India · doi:10.1016/j.mjafi.2021.06.021 · Cited by 195
The Epigenetic Hallmarks of Cancer
Esteller, M., Dawson, M. A., Kadoch, C., Rassool, F. V., Jones, P. A., & Baylin, S. B. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0296 · Cited by 202
A landscape of metabolic variation across tumor types
Reznik, E., Luna, A., Aksoy, B. A., Liu, E. M., La, K., Ostrovnaya, I., Creighton, C. J., Hakimi, A. A., & Sander, C. (2018) · Cell Systems · doi:10.1016/j.cels.2017.12.014 · Cited by 172
Metabolism unhinged: IDH mutations in cancer
Prensner, J. R., & Chinnaiyan, A. M. (2011) · Nature Medicine · doi:10.1038/nm0311-291 · Cited by 175
Mutant IDH1 and thrombosis in gliomas
Unruh, D. J., Schwarze, S. R., Khoury, L., Thomas, C., Wu, M., Chen, L., Chen, R., Liu, Y., Schwartz, M. A., Amidei, C., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1620-7 · Cited by 173
Self-citationLong-term reprogramming of the innate immune system
Domínguez‐Andrés, J., & Netea, M. G. (2018) · Journal of Leukocyte Biology · doi:10.1002/jlb.mr0318-104r · Cited by 182
Metabolic rewiring in melanoma
Ratnikov, B. I., Scott, D. A., Osterman, A. L., Smith, J. W., & Ronai, Z. A. (2016) · Oncogene · doi:10.1038/onc.2016.198 · Cited by 176
Sex Differences in Intestinal Carbohydrate Metabolism Promote Food Intake and Sperm Maturation
Hudry, B., de Goeij, E., Mineo, A., Gaspar, P., Hadjieconomou, D., Studd, C., Mokochinski, J. B., Kramer, H., Plaçais, P.-Y., Préat, T., et al. (2019) · Cell · doi:10.1016/j.cell.2019.07.029 · Cited by 164
Meta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2
Guilhamon, P., Eskandarpour, M., Halai, D., Wilson, G. A., Feber, A., Teschendorff, A. E., Gómez, V., Hergovich, A., Tirabosco, R., Amary, F. M., et al. (2013) · Nature Communications · doi:10.1038/ncomms3166 · Cited by 169
DNA demethylation pathways: Additional players and regulators
Bochtler, M., Kolano, A., & Xu, G. (2016) · BioEssays · doi:10.1002/bies.201600178 · Cited by 180
Oncogene-Directed Alterations in Cancer Cell Metabolism
Nagarajan, A., Malvi, P., & Wajapeyee, N. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.06.002 · Cited by 169
HIF-1-Independent Mechanisms Regulating Metabolic Adaptation in Hypoxic Cancer Cells
Lee, S.-H., Golinska, M., & Griffiths, J. R. (2021) · Cells · doi:10.3390/cells10092371 · Cited by 169
Personalized treatment strategies in glioblastoma: MGMT promoter methylation status
Thon, N., Kreth, S., & Kreth, F. W. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s50208 · Cited by 180
What do we know about IDH1/2 mutations so far, and how do we use it?
Horbinski, C. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1106-9 · Cited by 169
Chromatin accessibility: biological functions, molecular mechanisms and therapeutic application
Chen, Y., Liang, R., Li, Y., Jiang, L., Ma, D., Luo, Q., & Song, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02030-9 · Cited by 195
Tap, W. D., Villalobos, V. M., Cote, G. M., Burris, H., Janku, F., Mir, O., Beeram, M., Wagner, A. J., Jiang, L., Wu, B., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02492 · Cited by 165
Burr, S. P., Costa, A. S. H., Grice, G. L., Timms, R. T., Lobb, I. T., Freisinger, P., Dodd, R. B., Dougan, G., Lehner, P. J., Frezza, C., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.09.015 · Cited by 155
Thandapani, P. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.02.014 · Cited by 167
Wang, X., Liu, R., Qu, X., Yu, H. T., Chu, H., Zhang, Y., Zhu, W., Wu, X., Gao, H., Tao, B., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.07.007 · Cited by 167
Self-citationLiu, C., Liu, L., Chen, X., Shen, J., Shan, J., Xu, Y., Yang, Z., Wu, L., Xia, F., Bie, P., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062828 · Cited by 161
Self-citationLeonardi, R., Subramanian, C., Jackowski, S., & Rock, C. O. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.c112.353946 · Cited by 171
Sensing and Transmitting Intracellular Amino Acid Signals through Reversible Lysine Aminoacylations
He, X., Gong, W., Zhang, J., Nie, J., Yao, C.-F., Guo, F., Lin, Y., Wu, X., Li, F., Li, J., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.10.015 · Cited by 166
Self-citationMET in glioma: signaling pathways and targeted therapies
Cheng, F., & Guo, D. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1269-x · Cited by 167
DNA Hypomethylating Drugs in Cancer TherapyPreprint
Sato, T., Issa, J. J., & Kropf, P. L. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026948 · Cited by 169
Oncogenic regulation of tumor metabolic reprogramming
Tarrado‐Castellarnau, M., de Atauri, P., & Cascante, M. (2016) · Oncotarget · doi:10.18632/oncotarget.10911 · Cited by 165
Caravella, J. A., Lin, J., Diebold, R. B., Campbell, A.-M., Ericsson, A. M., Gustafson, G. R., Wang, Z., Castro, J., Clarke, A., Gotur, D., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01423 · Cited by 162
Kaelin, W. G. (2011) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2011.76.010975 · Cited by 161
Classification of adult‐type diffuse gliomas: Impact of the World Health Organization 2021 update
Whitfield, B. T., & Huse, J. T. (2022) · Brain Pathology · doi:10.1111/bpa.13062 · Cited by 172
Histone crotonylation promotes mesoendodermal commitment of human embryonic stem cells
Fang, Y., Xu, X., Ding, J., Yang, L., Doan, M. T., Karmaus, P. W. F., Snyder, N. W., Zhao, Y., Li, J., & Li, X. (2021) · Cell stem cell · doi:10.1016/j.stem.2020.12.009 · Cited by 158
Metabolic remodelling during early mouse embryo development
Zhao, J., Yao, K., Yu, H., Zhang, L., Xu, Y., Chen, L., Sun, Z., Zhu, Y., Zhang, C., Qian, Y., et al. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00464-x · Cited by 167
Self-citationMetabolic consequences of oncogenic IDH mutations
Parker, S. J., & Metallo, C. M. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.05.003 · Cited by 162
Gastric cancer: Metabolic and metabolomics perspectives (Review)
Xiao, S., & Zhou, L. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.4000 · Cited by 160
Low chorionic villous succinate accumulation associates with recurrent spontaneous abortion risk
Wang, X.-H., Xu, S., Zhou, X., Zhao, R., Lin, Y., Cao, J., Zang, W., Tao, H., Xu, W., Li, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23827-0 · Cited by 164
Self-citationInduction of sarcomas by mutant IDH2Preprint
Lü, C., Venneti, S., Akalin, A., Fang, F., Ward, P. S., Dematteo, R. G., Intlekofer, A. M., Chen, C., Ye, J., Hameed, M., et al. (2013) · Genes & Development · doi:10.1101/gad.226753.113 · Cited by 162
Personalized Proteomics: The Future of Precision Medicine
Duarte, T. T., & Spencer, C. T. (2016) · Proteomes · doi:10.3390/proteomes4040029 · Cited by 162
Borodovsky, A., Salmasi, V., Turcan, Ş., Fabius, A. W. M., Baía, G. S., Eberhart, C. G., WEINGART, J. D., Gallia, G. L., Baylin, S. B., Chan, T. A.-T., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.1408 · Cited by 158
Wu, M., Shi, L., Dubrot, J., Merritt, J., Vijay, V., Wei, T.-Y., Kessler, E., Olander, K. E., Adil, R., Pankaj, A., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1077 · Cited by 158
Epilepsy in glioma patients: mechanisms, management, and impact of anticonvulsant therapy: Table 1.
Armstrong, T. S., Grant, R., Gilbert, M. R., Lee, J. W., & Norden, A. D. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov269 · Cited by 157
Zhang, X., Rao, A., Sette, P., Deibert, C., Pomerantz, A., Kim, W. J., Kohanbash, G., Chang, Y., Park, Y., Engh, J. A., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now061 · Cited by 161
Glutamate and α-ketoglutarate: key players in glioma metabolism
Maus, A., & Peters, G. J. (2016) · Amino Acids · doi:10.1007/s00726-016-2342-9 · Cited by 162
Isocitrate dehydrogenase‐mutant glioma: Evolving clinical and therapeutic implications
Miller, J. J., Shih, H. A., Andronesi, O. C., & Cahill, D. P. (2017) · Cancer · doi:10.1002/cncr.31039 · Cited by 154
RNA-modifying proteins as anticancer drug targets
Boriack‐Sjodin, P. A., Ribich, S. A., & Copeland, R. A. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.71 · Cited by 157
The Roles of 2-Hydroxyglutarate
Du, X., & Hu, H. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.651317 · Cited by 160
Andronesi, O. C., Loebel, F., Bogner, W., Marjańska, M., Heiden, M. G. V., Iafrate, A. J., Dietrich, J., Batchelor, T. T., Gerstner, E. R., Kaelin, W. G., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0656 · Cited by 153
Teicher, B. A., Linehan, W. M., & Helman, L. J. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2587 · Cited by 152
Folate cycle enzyme MTHFD1L confers metabolic advantages in hepatocellular carcinoma
Lee, D., Xu, M., Chiu, D. K., Lai, R. K., Tse, A. P., Li, L. L., Law, C., Tsang, F. H., Wei, L. L., Chan, C. Y., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci90253 · Cited by 153
Song, Y., Wu, F., & Wu, J. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0279-9 · Cited by 154
Induction of innate immune memory: the role of cellular metabolism
Domínguez‐Andrés, J., Joosten, L. A. B., & Netea, M. G. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.09.001 · Cited by 152
Oncometabolites‐driven tumorigenesis: From genetics to targeted therapy
Morin, A., Letouzé, É., Gimenez‐Roqueplo, A., & Favier, J. (2014) · International Journal of Cancer · doi:10.1002/ijc.29080 · Cited by 162
Bardella, C., Al‐Dalahmah, O., Krell, D., Brazauskas, P., Al‐Qahtani, K., Tomková, M., Adam, J., Serres, S., Lockstone, H. E., Freeman-Mills, L., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.08.017 · Cited by 157
Isocitrate Dehydrogenase Mutations in Glioma: From Basic Discovery to Therapeutics Development
Huang, J., Yu, J., Tu, L., Huang, N., Li, H., & Luo, Y. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00506 · Cited by 147
Metabolic Abnormalities in Glioblastoma and Metabolic Strategies to Overcome Treatment Resistance
Zhou, W., & Wahl, D. R. (2019) · Cancers · doi:10.3390/cancers11091231 · Cited by 152
Radioprotection of IDH1 -Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198
Molenaar, R. J., Botman, D., Smits, M. A., Hira, V. V., van Lith, S. A., Stap, J., Henneman, P., Khurshed, M., Lenting, K., Mul, A. N., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3603 · Cited by 148
PHGDH amplification and altered glucose metabolism in human melanoma
Mullarky, E., Mattaini, K. R., Heiden, M. G. V., Cantley, L. C., & Locasale, J. W. (2011) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2011.00919.x · Cited by 153
Kraus, T. F. J., Globisch, D., Wagner, M., Eigenbrod, S., Widmann, D., Münzel, M., Müller, M., Pfaffeneder, T., Hackner, B., Feiden, W., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27429 · Cited by 146
Dysregulation of the TET family of epigenetic regulators in lymphoid and myeloid malignancies
Lio, C. J., Yuita, H., & Rao, A. (2019) · Blood · doi:10.1182/blood.2019791475 · Cited by 152
Takai, H., Masuda, K., Sato, T., Sakaguchi, Y., Suzuki, T., Suzuki, T., Koyama‐Nasu, R., Nasu‐Nishimura, Y., Katou, Y., Ogawa, H., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.08.071 · Cited by 151
Fack, F., Tardito, S., Hochart, G., Oudin, A., Zheng, L., Fritah, S., Golebiewska, A., Nazarov, P. V., Bernard, A., Hau, A., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201707729 · Cited by 148
Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China
Wang, J.-H., Chen, W., Li, J., Wu, S., Chen, T., Zhu, Y., Zhang, W., Li, Y., Qiu, Y.-P., Zhao, A.-H., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1315558110 · Cited by 146
Self-citationKarlstaedt, A., Zhang, X., Vitrac, H., Harmancey, R., Vasquez, H., Wang, J. H., Goodell, M. A., & Taegtmeyer, H. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1601650113 · Cited by 144
Emerging novel functions of the oxygen-sensing prolyl hydroxylase domain enzymes
Wong, B. W., Kuchnio, A., Brüning, U., & Carmeliet, P. (2012) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2012.10.004 · Cited by 144
Oncometabolites: tailoring our genes
Nowicki, S., & Gottlieb, E. (2015) · FEBS Journal · doi:10.1111/febs.13295 · Cited by 148
Proteomic Portrait of Human Breast Cancer Progression Identifies Novel Prognostic Markers
Geiger, T., Madden, S. F., Gallagher, W. M., Cox, J., & Mann, M. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3711 · Cited by 144
Gorovets, D. J., Kannan, K. S., Shen, R., Kastenhuber, E. R., Islamdoust, N., Campos, C., Pentsova, E. I., Heguy, A., Jhanwar, S. C., Mellinghoff, I. K., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2977 · Cited by 145
Bady, P., Delorenzi, M., & Hegi, M. E. (2016) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2015.11.009 · Cited by 144
Acidic pH Is a Metabolic Switch for 2-Hydroxyglutarate Generation and Signaling
Nadtochiy, S. M., Schafer, X., Fu, D., Nehrke, K., Munger, J., & Brookes, P. S. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.738799 · Cited by 143
Oncogenic Activities of IDH1/2 Mutations: From Epigenetics to Cellular Signaling
Gagné, L. M., Boulay, K., Topisirović, I., Huot, M., & Mallette, F. A. (2017) · Trends in Cell Biology · doi:10.1016/j.tcb.2017.06.002 · Cited by 143
Metadata
- Authors
- Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., Liu, L.-X., Jiang, W.-Q., Liu, J., Zhang, J.-Y., Wang, B., Frye, S., Zhang, Y., Xu, Y.-H., Lei, Q.-Y., Guan, K.-L., Zhao, S.-M., & Xiong, Y.
- Affiliations
- Shanghai Medical College of Fudan University (CN)
- University of North Carolina at Chapel Hill (US)
- Chinese Academy of Sciences (CN)
- Corresponding author
- Guan, Kun-Liang
- Xiong, Yue
- ORCID
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2011-01
- Volume
- 19
- Issue
- 1
- Pages
- 17-30
- ISSN
- 1535-6108 (ISSN-L)
- PMC
- PMC3229304
- OpenAlex
- W2131860315
- Cited by
- 2,875
- References
- 55
- Citations by year
- 2026: 165 · 2025: 168 · 2024: 192 · 2023: 182 · 2022: 183 · 2021: 270 · 2020: 214 · 2019: 191 · 2018: 195 · 2017: 183 · 2016: 196 · 2015: 180 · 2014: 183 · 2013: 157 · 2012: 137
- FWCI
- 90.25
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 928 d)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- Cancer Cell (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- National Natural Science Foundation of China (11079016, 30600112, 30871255, 30971485/C0706)
- Ministry of Education of the People's Republic of China
- National Key Research and Development Program of China (2011CB910600, 2011CB965300)
- Project 985
- Major State Basic Research Development Program of China (2009CB918401, 2009CB918600)
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- 2-hydroxyglutarate, oncometabolites, alpha-ketoglutarate-dependent dioxygenase, IDH1 mutation, IDH2 mutation, histone demethylase, 5-hydroxymethylcytosine, competitive inhibition, glioma, acute myeloid leukemia, DNA methylation, histone methylation, active site
- MeSH terms
- Animals, Binding, Competitive, Cytosine, DNA-Binding Proteins, Glioma, Glutarates, Histones, Humans, Mixed Function Oxygenases, Isocitrate Dehydrogenase, Ketoglutaric Acids, Models, Molecular, Oxalates, Oxidoreductases, N-Demethylating, Procollagen-Proline Dioxygenase, Proto-Oncogene Proteins, Gene Expression, Caenorhabditis elegans, Homeodomain Proteins, Amino Acid Substitution, Catalytic Domain, Caenorhabditis elegans Proteins, Endostatins, 5-Methylcytosine, F-Box Proteins, Cell Line, Tumor, Dioxygenases, Hypoxia-Inducible Factor 1, alpha Subunit, Biocatalysis, Histone Demethylases, Jumonji Domain-Containing Histone Demethylases, Hypoxia-Inducible Factor-Proline Dioxygenases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
